Basilea Pharmaceutica AG Statistics

Total Valuation

Basilea Pharmaceutica AG has a market cap or net worth of CHF 489.09 million. The enterprise value is 538.57 million.

Market Cap	489.09M
Enterprise Value	538.57M

Important Dates

The last earnings date was Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Basilea Pharmaceutica AG has 12.12 million shares outstanding. The number of shares has decreased by -6.73% in one year.

Current Share Class	n/a
Shares Outstanding	12.12M
Shares Change (YoY)	-6.73%
Shares Change (QoQ)	+15.14%
Owned by Insiders (%)	0.05%
Owned by Institutions (%)	35.74%
Float	12.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	9.21
PS Ratio	3.26
PB Ratio	29.14
P/TBV Ratio	n/a
P/FCF Ratio	52.39
P/OCF Ratio	n/a
PEG Ratio	0.33

Financial Ratio History

Enterprise Valuation

EV / Earnings	-826.03
EV / Sales	3.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	57.69

Financial Position

The company has a current ratio of 4.10, with a Debt / Equity ratio of 6.70.

Current Ratio	4.10
Quick Ratio	2.96
Debt / Equity	6.70
Debt / EBITDA	n/a
Debt / FCF	12.05
Interest Coverage	-0.87

Financial Efficiency

Return on equity (ROE) is -4.10% and return on invested capital (ROIC) is -2.73%.

Return on Equity (ROE)	-4.10%
Return on Assets (ROA)	-2.05%
Return on Capital (ROIC)	-2.73%
Revenue Per Employee	955,269
Profits Per Employee	-4,179
Employee Count	147
Asset Turnover	0.71
Inventory Turnover	4.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +10.57% in the last 52 weeks. The beta is 0.70, so Basilea Pharmaceutica AG's price volatility has been lower than the market average.

Beta (5Y)	0.70
52-Week Price Change	+10.57%
50-Day Moving Average	44.16
200-Day Moving Average	41.29
Relative Strength Index (RSI)	30.74
Average Volume (20 Days)	29,490

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Basilea Pharmaceutica AG had revenue of CHF 149.02 million and -652,000 in losses. Loss per share was -0.05.

Revenue	149.02M
Gross Profit	24.12M
Operating Income	-6.86M
Pretax Income	-14.08M
Net Income	-652,000
EBITDA	-5.60M
EBIT	-6.86M
Loss Per Share	-0.05

Full Income Statement

Balance Sheet

The company has 62.96 million in cash and 112.45 million in debt, giving a net cash position of -49.48 million or -4.08 per share.

Cash & Cash Equivalents	62.96M
Total Debt	112.45M
Net Cash	-49.48M
Net Cash Per Share	-4.08
Equity (Book Value)	16.79M
Book Value Per Share	1.38
Working Capital	117.23M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.30 million and capital expenditures -966,000, giving a free cash flow of 9.34 million.

Operating Cash Flow	10.30M
Capital Expenditures	-966,000
Free Cash Flow	9.34M
FCF Per Share	0.77

Full Cash Flow Statement

Margins

Gross margin is 16.19%, with operating and profit margins of -4.60% and -0.44%.

Gross Margin	16.19%
Operating Margin	-4.60%
Pretax Margin	-9.45%
Profit Margin	-0.44%
EBITDA Margin	-3.76%
EBIT Margin	-4.60%
FCF Margin	6.26%

Dividends & Yields

Basilea Pharmaceutica AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	6.73%
Shareholder Yield	6.73%
Earnings Yield	-0.13%
FCF Yield	1.91%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Basilea Pharmaceutica AG has an Altman Z-Score of -4.21. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.21
Piotroski F-Score	n/a